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Barcelona, 08193 Bellaterra, SpainPhotoreceptor loss is the principal cause of blindness in retinal
degenerative diseases (RDDs). Whereas some therapies exist
for early stages of RDDs, no effective treatment is currently
available for later stages, and once photoreceptors are lost,
the only option to rescue vision is cell transplantation. With
the use of the Royal College of Surgeons (RCS) rat model of
retinal degeneration, we sought to determine whether com-
bined transplantation of human-induced pluripotent stem
cell (hiPSC)-derived retinal precursor cells (RPCs) and retinal
pigment epithelial (RPE) cells was superior to RPE or RPC
transplantation alone in preserving retinal from degeneration.
hiPSC-derived RPCs and RPE cells expressing (GFP) were
transplanted into the subretinal space of rats. In vivo moni-
toring showed that grafted cells survived 12 weeks in the subre-
tinal space, and rats treated with RPE + RPC therapy exhibited
better conservation of the outer nuclear layer (ONL) and visual
response than RPE-treated or RPC-treated rats. Transplanted
RPE cells integrated in the host RPE layer, whereas RPCmostly
remained in the subretinal space, although a limited number of
cells integrated in the ONL. In conclusion, the combined trans-
plantation of hiPSC-derived RPE and RPCs is a potentially
superior therapeutic approach to protect retina from degener-
ation in RDDs.Received 1 July 2020; accepted 4 February 2021;
https://doi.org/10.1016/j.omtm.2021.02.006.
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Retinal degenerative diseases (RDDs) are a heterogeneous group of
pathologies characterized by the progressive degeneration of photore-
ceptors (PRs), ultimately leading to blindness,1 and affect 285 million
people worldwide.
Cone and rod photoreceptors are the light-sensing cells in the retina
and are responsible for visual input.2 In close association with the
photoreceptors, the retinal pigment epithelium (RPE) provides
them several crucial supporting functions, including: recycling of688 Molecular Therapy: Methods & Clinical Development Vol. 20 March
This is an open access article under the CC BY-NC-ND license (httpall-trans retinol to 11-cis retinal in the visual cycle, phagocytosis of
photoreceptor outer segments (POS), or light absorption, among
others.3 Photoreceptor loss in RDDs may be the result of photore-
ceptor dysfunction or may result from RPE loss or dysfunction.
Nowadays, treatment strategies are mainly focused on the early stages
of the diseases, preventing retinal degeneration through neuroprotec-
tion and gene therapies. To date, there is no effective treatment
capable to revert cell death and restore visual function in later stages;
thus, research in cell-based therapies for retina regeneration has been
the subject of intense investigation.
Mammalian retinas have limited regenerative capacity,4 and cell-
based therapies aiming to restore light sensitivity are highly desirable.
Human pluripotent stem cells (hPSCs), both embryonic (hESC) or
induced (hiPSC), can differentiate into any retinal cell type and can
thus serve as a renewable cell source to repair degenerated retinas.5,6
In this context, hESC-derived RPE cell transplantation has been suc-
cessful in several preclinical models,6 although long-term efficacy has
yet to be defined. Likewise, several clinical trials in age-related macu-
lar degeneration (AMD), retinitis pigmentosa, and Stargardt’s disease
have been proven safe but with only limited improvements in
vision.7–10 These results likely suggest that at later disease stages,
when photoreceptors have degenerated, transplanted RPE cells are
unable to rescue vision, since they are not light sensing cells. Thus,
several photoreceptor-replacement therapies have been explored to
overcome this limitation, including full-thickness retinal patches,11–
14 retinal progenitor cells,15–17 neural progenitor cells,18,19 and stem2021 ª 2021 The Author(s).
://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Characterization of human-induced pluripotent stem cell (hiPSC)-derived retinal pigment epithelium (RPE) cells
(A) RPE-like cells exhibited typical pigmented hexagonal cell morphology under bright-field and expressed green fluorescent protein (GFP). Representative immunostaining
images show expression of RPE markers bestrophin-1 (BEST1), ZO-1 (zonula occludens 1), MITF (microphthalmia-associated transcription factor), and a human antigen
(Ku80). Nuclei are stained with DAPI. Scale bars, 75 mm in left panels and 50 mm in middle and right panels. (B) Gene-expression levels in RPE-like cells by quantitative real-
time PCR. Values are normalized toGAPDH and relative to undifferentiated hiPSC, expressed as 2DDCt (log scale). Data presented asmean ± standard deviation (SD; n = 3),
five independent biological replicates. (C) Quantitative analysis by flow cytometry of RPE65, MITF, and BEST1 in RPE cell culture. Histograms show both the undifferentiated
hiPSC (blue) and RPE cells (red). Results are representative of two independent experiments performed with cells from different differentiations. (D) Representative trans-
mission electron microscopy (TEM; ac) and scanning electron microscopy (SEM; df) images of RPE cells in culture. RPE monolayers show polarization with apical
microvilli, melanosomes, mitochondria, tight junction (red arrow), and adherent junction (red arrowhead) at the apical border and basal nuclei (N). Scale bars, 2 mm (a and b)
and 0.2 mm (c) for TME images. Scale bars, 10 mm (d), 5 mm (e), and 0.5 mm (f) for SEM images. (E) In vitro phagocytosis of tetramethylrhodamine (TRITC)-labeled
photoreceptor (PR) outer segments (POS; red) by RPE-like cells (GFP in green). Nuclei are stained with DAPI. Scale bar, 25 mm.
www.moleculartherapy.orgcell-derived retinal progenitors,20–34 which have been proven to
restore visual function in animal models of photoreceptor dysfunc-
tion. The majority of cell replacement strategies are currently based
on transplantation of a single cell-type rather than multiple cell types;
however, in the setting of defective RPE, transplantation of photore-
ceptors only might not be sufficient without a healthy RPE support. In
that case, selective replacement of both RPE and photoreceptor cell
types might be a better strategy to regenerate the retinas.MolecularThe Royal College of Surgeons (RCS) rat model of autosomal-reces-
sive retinitis pigmentosa has been extensively used for cell therapeutic
approaches, since it is a good model for developing cell therapies
focused on severe retinopathies. RCS rats carry a defective MERTK
gene,35 a receptor tyrosine kinase expressed in RPE cells, which leads
to RPE malfunction of phagocytosis of POS that in turn trigger severe
photoreceptor cell death, beginning at 3 weeks after birth and
continuing rapidly over 4 weeks.36,37 We previously demonstratedTherapy: Methods & Clinical Development Vol. 20 March 2021 689
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www.moleculartherapy.orgthe potential of hESC and hiPSC to generate transplantable RPE cells,
but these cells failed to exert significant long-term improvement of vi-
sual function.38 In the current study, we developed a protocol to
generate both retinal precursor cells (RPCs), consisting mainly in
photoreceptor precursor cells, and RPE cells from hiPSC. Our main
objective was to assess whether a cell-transplantation strategy using
a combination of RPE cells and RPC would be superior to RPE or
RPC therapies alone using the RCS rat model and to explore the po-
tential of our RPC to integrate and repopulate the degenerative
endogenous photoreceptor layer.RESULTS
Differentiation and characterization of RPE-like cells derived
from hiPSCs
Previously, we successfully differentiated hESCs and hiPSCs to RPE-
like cells.38 With the use of the same protocol here, we obtained a ho-
mogeneous culture of RPE cells recapitulating the native cellular
morphology, including a characteristic pigmented polygonal cell
shape (Figure 1A). To facilitate in vivo detection of transplanted cells,
we transduced RPE cells with lentiviral particles carrying a GFP re-
porter gene. RPE cells in culture constitutively expressed GFP and
the human nuclear antigen Ku80 (Figure 1A). RPE cells also ex-
pressed specific early ocular markers, including PAX6, OTX2,
MITF, and CHX10, and the mature RPE markers bestrophin-1,
RPE65, ZO-1, SIL, PEDF, MERTK, and TYR and showed downregu-
lation of OCT4 and Tra-1-60 (Figures 1A1C). Along maturation,
the RPE cell monolayer polarized and acquired apical-basolateral
specialization, columnar-shape morphology with apical melanin-
containing melanosomes and tight junctions, as observed by trans-
mission electron microscopy (TEM) (Figure 1D, ac). Microvilli
were also observed in the apical side by scanning electron microscopy
(SEM) (Figure 1D, df). As RCS rats carry a defective mertk gene,
which is essential for RPE to phagocytize POS, we ensured that the
hiPSC-derived RPE cells exhibited native phagocytic function before
transplantation, as demonstrated by their internalization of tetrame-
thylrhodamine (TRITC)-labeled POS in vitro (Figure 1E). Overall,
these results show that the RPE cell-differentiation protocol is robust,
reproducible, and generates functional RPE-like cells.Figure 2. Generation and characterization of retinal precursor cells (RPCs) fro
(A) Schematic diagram of the three-step protocol at different stages of differentiation. B
embryoid bodies at day 1, early retinal rosettes containing RPCs at day 10, and optic cu
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MolecularDifferentiation and characterization of RPCs derived from
hiPSCs
To guide hiPSCs to the retinal lineage, we used a differentiation pro-
tocol based on a previous study (Figure 2A).39 Upon neuroretina in-
duction, embryoid bodies (EBs) were seeded onto Matrigel to develop
an anterior neuroepithelium, followed by neural rosette formation
observed by day 7. Early neural retina and optic cups were apparent
by day 25 of culture and showed signs of internal lamination
surrounded by a few pigmented cells at day 60 of differentiation
(Figure 2A). We characterized retinal cells at different time points
by immunocytochemistry, qRT-PCRquantitative real-time PCR, and
flow cytometry. At day 21 of differentiation, cell culture comprised
retinal progenitor cells that formed neural rosettes and neuroepithe-
lium (Figure 2B). Retinal progenitors expressed the early-stage-spe-
cific markers PAX6, RAX, CHX10, and OTX2 and the photoreceptor
progenitor markers CRX, recoverin, and NLR and showed a decrease
in the expression of the pluripotency genes OCT4, NANOG, and Tra-
1-60 (Figures 2B and 2C; Figure S1A). At this stage, retinal progenitors
were proliferative (Ki67+), as it is shown by flow cytometry (Fig-
ure S1A). At days 4550, cell culturewas composed of a homogeneous
population ofmoremature retinal cells, hereinafter RPCs, which along
with GFP (cells transduced with lentivirus before transplantation),
RAX, CHX10, and PAX6, together with CRX and NRL expression,
we detected cell clusters containing recoverin + cells (Figures
2D2F). Within RPC cultures, recoverin + photoreceptor precursors
had extended axonal projections (arrows inmagnification; Figure 2D).
Furthermore, we could detect expression ofOPSIN and RHODOPSIN
transcripts by quantitative real-time PCR (Figure 2E), similar to
another study.34 Flow cytometry analysis revealed that theRPCmostly
expressed recoverin, red/green coneopsin (RG-OPSIN), and PAX6,
whereas a smaller proportion (1.1%) expressed rhodopsin (Figure 2F).
Themanifestation of pigmented foci in our cultures, corresponding to
RPE cells, was observed from day 30, although the percentage of pig-
mented RPE was relatively low, as demonstrated by flow cytometry at
day 45 with only 0.4% of total cells. Moreover, RPC at day 45 was not
mitotically active, as it is shown by the low Ki67 levels (1.5%) (Fig-
ure 2F). At day 90 of differentiation, retinal cell cultures showed
mature photoreceptor cells expressing CRX, recoverin rhodopsin,
and RG-opsin, and these cells also presented longer axonal projectionsm hiPSCs
right-field images of cell morphology of undifferentiated hiPSC colonies at day 5,
p-like structures at day 60. Scale bars, 500 mm and 100 mm. (B) At day 21, confocal
u80; eye-field primordial and neural retinamarkers SOX1, CHX10, OTX2, and PAX6;
f gene expression at day 21 relative to undifferentiated hiPSC shows downregulation
CHX10) and photoreceptor (CRX, RAX, and recoverin [Recov]) genes. Values are
cale). Data presented as mean ± SD (n = 3), three independent biological replicates.
ansduced with the lentivirus SparQ-GFP at day 45 (before transplantation). The
arkers (NRL, RECOV, and CRX) is shown. Magnification of Recov + cells with axonal
agnifications. Nuclei are stained with DAPI. (E) uantitative real-time PCR of gene
pluripotent genes (NANOG and OCT4) but upregulation of retinal markers, including
o undifferentiated hiPSC, expressed as 2DDCt (log scale). Data presented asmean ±
is of RPC at day 45 with surface marker Tra-1-60 and intracellular markers RECOV,
n) and the appropriate controls (undifferentiated hiPSC, retinal progenitors at day 21,
percentage of stained cells in this gate. Secondary antibody was used as control.
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Table 1. Groups of transplanted RCS rats at postnatal days 21–24
Experiment Treatment (cell suspension injection) No. of injected cells No. of rats No. of successfully injected eyes Successful injection rates
#1
RPE 105 13 20 77%
RPE + RP d21 5  104 + 5  104 20 34 85%
RPE + RPC d45–50 5  104 + 5  104 20 13 64%
RPE + RPC d75 5  104 + 5  104 17 28 82%
Sham  15 21 70%
#2
RPE 105 20 30 75%
RPE + RPC d4550 5  104 + 5  104 23 32 70%
RPC d4550 105 8 11 68%
Sham  10 15 75%
RPE, retinal pigment epithelium; RP, retinal progenitor; RPC, retinal precursor cell; d21, day 21 of differentiation; d45–50, days between 45 and 50 of differentiation; d75, day 75 of
differentiation.
Molecular Therapy: Methods & Clinical Developmentas compared with day 45 (Figure S1B) This indicated that our protocol
enriches for a population of RG cone photoreceptors.
Establishing the optimal RPC developmental time window for
transplantation
Studies have shown that the maturity of stem cell-derived photore-
ceptors is key for successful engraftment, maturation, and function
in the correct host retinal layer.24,28 Thus, we first determined the
best retinal cells’ differentiation time window to improve retinal con-
servation and visual function recovery in the RCS model. In a pilot
study (Table 1, experiment 1), we cotransplanted hiPSC-derived
RPE cells together with retinal progenitors at day 21, RPC at days
4550, and more mature RPC at day 75; RPE cells alone; or medium
(sham) into the subretinal space of RCS rats at postnatal days between
21 and 24, corresponding to the initial stages of photoreceptor degen-
eration. We then analyzed visual function by electroretinography
(ERG) and retina conservation by histology at 8 and 12 weeks post-
transplantation (Figure S2). Cotransplantation of RPE + RPC at
days 45–50 and day 75 of differentiation led to a significant preserva-
tion of visual function at 12 weeks compared with RPE-transplanted
rats and the sham group (p < 0.05) and was superior to that in retinas
transplanted with RPE + retinal progenitors at day 21 (Figures
S2AS2C). We also observed a better preservation of the outer nu-
clear layer (ONL) from 8 to 12 weeks with RPE + RPC differentiated
for 45–50 days or for 75 days when compared with RPE + retinal pro-
genitors differentiated for 21 days, RPE cells alone, or sham (Fig-
ure S2D). These data suggest that day 21 differentiated retinal progen-
itor cultures consist of immature progenitors that fail to preserve or
improve retinal function and that RPC days 45–75 cultures consist
of precursor cells at an equivalent stage of development to those of
RCS rats. Based on these results, we established our transplantable
developmental time window at days 45–50.
Transplanted RPE +RPCs survive in the subretinal space of RCS
rats and can be monitored in vivo over 12 weeks
In a second experiment, we performed a comprehensive study of the
progression, survival, and integration of transplanted cells in the RCS692 Molecular Therapy: Methods & Clinical Development Vol. 20 Marchmodel (Table 1; experiment 2). Four groups of RCS rats were subreti-
nally injected with cell suspensions of RPE cells, RPC cells at days
45–50 of differentiation, a combination of RPE cells and RPC, or me-
dium. All transplanted cells expressed GFP, and the injected eyes were
periodically monitored by fluorescence fundus imaging (FFI) and op-
tical coherence tomography (OCT) for 12 weeks. We first followed
the presence and evolution of cell grafts in the host retinas (Figure 3).
In all groups, retinas appeared detached and formed a subretinal bleb
(Figures 3A3C, a and b) containing the injected cell suspension.
1 week after injection, the bleb was absorbed, and cell grafts were de-
tected as fluorescent dots randomly distributed around the injection
area (Figures 3A3C, c and d). 2 weeks postinjection, retinas had
almost recovered their natural position, and the fluorescent clumps
seemed to be partially reduced in size (Figures 3A3C, e and f).
The level of fluorescence remained very similar from 4 to 12 weeks
in the RPE + RPC group, indicating the survival of most of the cells
present at week 2 (Figure 3C, gl). However, the fluorescent cell
grafts in the RPE and the RPC groups were reduced drastically
from 4 weeks after transplantation (Figures 3A and 3B, g and h),
and very few green cells were observed at 12 weeks (Figures 3A and
B, k and l) even though rats were under immunosuppression, stating
the difficulty of RPE or RPC survival when transferred alone in the
retina of the RCS model.
Combined RPE + RPC therapy induces a better survival of
endogenous photoreceptors than RPC or RPE cell therapies
The RCS rat model is primarily characterized by severe degeneration
of photoreceptors as a consequence of the RPE cell dysfunction,
which can be easily observed by OCT at postnatal day 60.40 To eval-
uate whether RPE + RPC, RPC, or RPE cell therapies could rescue
photoreceptor degeneration, we examined the total retina thickness
and the photoreceptor layer thickness (consisting of ONL + outer
and inner photoreceptor segments) in all groups. Quantifications
were performed at 4 weeks (Figures 4A4F), 8 weeks (Figures
4G4L), and 12 weeks (Figures 4M4R) postinjection, and retinal
preservation of the grafted area was normalized by the thickness of
the contralateral area of the same eye and compared between groups.2021
Figure 3. In vivo time course of GFP-fluorescent cell survival in the subretinal space of the RCS rat
(A) Images from the same eye injected with RPE cells alone at 1, 2, 4, 8, and 12 weeks postinjection (PI). (B) Images from the same eye injected with RPC alone. (C) Images
from the same eye injected with the combination of RPE + RPC alone. Images show fundus retinographies (a, c, e, g, i, and k) and fluorescent retinographies under blue filter
(b, d, f, h, j, and l) in the same area, where grafted GFP+ cells are observed as green spots.
www.moleculartherapy.orgAt 4 weeks after transplantation, retinal micrographs showed no dif-
ferences in terms of retina preservation among the four groups (Fig-
ure 4E). Conversely, at 8 and 12 weeks postinjection, we observed a
significant rescue of the total retina (Figures 4K and 4Q) and photo-
receptor layer thickness (Figures 4L and 4R) in the group treated with
combined RPE + RPC compared with RPC, RPE, and sham groups.
Moreover, at 12 weeks, the RPC group exhibited a marked reduction
of both total retina and ONL thickness compared to 8 weeks (Figures
4Q and 4R). Of note, we did not observe any nuclei in the ONL of
sham-injected eyes36 at 12 weeks postinjection, whereas we detected
some nuclear layers in RPE-, RPC-, and RPE + RPC-transplanted
eyes (Figures 4M4P). In summary, combined RPE + RPC cell ther-
apy is better at preserving retinas from degeneration than RPE and
RPC cell therapies.MolecularCombined RPE + RPC therapy preserves visual function better
than RPC or RPE cell therapies alone
We previously showed that RPE transplantation in the subretinal
space of RCS rats partially preserved retinal function up to 8 weeks
postinjection.38 To assess whether combined RPE + RPC therapy
was superior to RPC or RPE cell transplantation at preserving re-
sponses to light stimuli, we compared the electrical response of the
different treatment groups by scotopic ERG at 4, 8, and 12 weeks post-
injection (Figures 5A5C). Animals were stimulated with green light
from 1.1 to 1.9 log cd $ s $m2 to acquire the best retinal response,
and ERG waves were analyzed by amplitude and implicit time quan-
tification (Figures 5D5G). Measurements shown in Figure 4 are
those corresponding to 1.9 log cd $ s $m2. At 4 weeks postinjection,
ERG responses obtained from RPE and RPE + RPC cell-engraftedTherapy: Methods & Clinical Development Vol. 20 March 2021 693
Figure 4. Structural analysis of transplanted retinas by optical coherence tomography (OCT)
Eyes injected with medium (sham; A, G, and M; n = 6 eyes), RPE cells (B, H, and N; n = 8 eyes), RPC (C, I, and O; n = 6 eyes), or the combination of RPE and RPC (RPE +
RPCs; D, J, and P; n = 10 eyes) were analyzed at 4, 8, and 12 weeks PI by OCT, obtaining retina micrographs of the grafted area and a contralateral area of the same eye (not
shown). Cross-sections of the retinas were analyzed, quantifying total retina thickness (TOTAL RETINA; area between blue and orange lines) and PR layer thickness (PR
LAYER; area between green and orange lines). The preservation of the thickness of total retina and PR layer was compared among groups at 4 (E and F), 8 (K and L), and
12 weeks PI (Q and R), calculating the difference between the grafted area and the contralateral area of the same eye. Data presented as mean ± SD. Statistical significance
was calculated by one-way ANOVA, followed by Tukey’s multiple comparison tests. *p < 0.05; **p < 0.005 between RPE + RPC and sham groups; #p < 0.05; ##p < 0.005
between RPE + RPC and RPE groups.
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Figure 5. Visual function analysis by electroretinogram
(AC) Representative electroretinogram recordings at 4, 8, and 12 weeks PI. Scotopic electroretinogram responses were recorded from eyes injected with medium (sham;
blue lines, n = 7 eyes), RPE-differentiated cells (RPE; red lines, n = 8 eyes), RPC-differentiated cells (RPC; green lines, n = 8 eyes), or the combination of RPE and RPCs (RPE +
RPC; black lines, n = 9 eyes). Measurements were recorded under a light stimulus of 1.9 log cd $ s $ m2 and 1 ms of duration. (DG) Electroretinographic waves were
quantified and compared among treatment groups at the three time points by the measurement of the b-wave amplitude (D) and its implicit time (F) and the a-wave amplitude
(E) and its implicit time (G). Data presented as mean ± SD. Statistical significance was calculated by two-way ANOVA, followed by Tukey’s multiple comparison tests
comparing shamwith RPE, RPC, and RPE +RPC data (*), comparing RPEwith RPE +RPC data (#), or comparing RPCwith RPE +RPC data (+). *p < 0.05; **p < 0.005; ***p <
0.0005; ****p < 0.0001; #p < 0.05; ##p < 0.005; ###p < 0.0005; +p < 0.05; ++p < 0.005; +++p < 0.0005.
www.moleculartherapy.orgeyes were clearly higher than those obtained from sham-injected eyes,
exhibiting a significantly higher b-wave and a significantly shorter im-
plicit time (Figures 5D5F). However, RPC-engrafted eyes did not
produce significantly better ERG signals at 4 weeks. Furthermore,
eyes injected with the RPE + RPC combination showed a better
b-wave response than eyes injected with RPE and PRC alone (Fig-
ure 5D). This significant improvement in the visual function by
combined therapy was consistent until 12 weeks postinjection. Never-
theless, the retinal signal of all animals inevitably decreased along this
time period, likely due to the progressive retinal neurodegeneration
of the model and the effect of immunosuppression with cyclosporin
A, which has been shown to reduce visual response in RCS rats.40
A-wave amplitudes at 4 weeks postinjection were significantly betterMolecularin the RPE + RPC cell-injected group than in the sham group, and this
significance was also observed at 12 weeks postinjection (Figure 5E).
In addition, the implicit time of the a-wave was significantly shorter in
all of the cell-injected groups compared to the sham group at all three
time points assessed, indicating a faster response with the cell thera-
pies (Figure 5G). Overall, the functional results obtained by ERG
demonstrate the superiority of the combined RPE + RPC therapy
over the RPE and the RPC cell therapies alone in preserving visual
function over 12 weeks after transplantation.
RPC and RPE cells integrate in the degenerating rat retina
Consistent with the OCT data, postmortem histological analyses of
eyes transplanted with RPE + RPC at 8 and 12 weeks revealedTherapy: Methods & Clinical Development Vol. 20 March 2021 695
Figure 6. Postmortem analysis of RPE and RPC integration in the RCS rat retina
(A) Hematoxylin and eosin of rat eye cryosections injected with sham (control), RPE cells, RPC, and RPE + RPC at 8 weeks (a) and 12 weeks (b) PI (n = 3 eyes/group). Scale
bar, 50 mm. (B) Immunofluorescence analysis of Rho, blue opsin, RPE65, and Recov in sections of RCS rat retinas at 8 weeks PI with sham (control), RPE cells, RPC, and
RPE + RPC cell suspensions. Scale bars, 25 mm. (C) Immunofluorescence staining with Rho, blue opsin, RPE65, and Recov in sections of RCS rat retinas at 12 weeks PI with
sham (control), RPE, RPC, and RPE + RPC cell suspensions. Brackets indicate outer nuclear layer (ONL). Scale bars, 25 mm. Nuclei were stained with DAPI. (D) Quantification
of ONL nuclei rows (top graph) and ONL thickness (bottom graph) in retinal paraffin sections (n = 35 eyes/group). Data are expressed as mean ± SD. *p < 0.01; ***p <
0.0005; **p < 0.001 versus 8weeks; #p < 0.01; ##p < 0.001 versus control at 8 weeks; yp < 0.05; yyp < 0.00001 versus control at 12 weeks, calculated using Student’s t test.
GCL, ganglion cell layer; INL, inner nuclear layer.
Molecular Therapy: Methods & Clinical Developmentextensive conservation of the photoreceptor layer that extended
around the injection site, and this was better compared to that of
the eyes transplanted with RPC or RPE cells only (Figure S3A). At
8 weeks postinjection, we observed well-defined engrafted cell clusters
containing pigmented cells in both RPE + RPC and RPE cell groups
but not in the RPC group (Figure 6A, a). The rescue of the photore-
ceptor layer was more manifest at 12 weeks postinjection (Figure 6A,
b). Flat-mounted RPE layers of eyes injected with RPE + RPC showed696 Molecular Therapy: Methods & Clinical Development Vol. 20 Marchthat engrafted RPE cells were distributed in GFP+ cell patches, similar
to what we observed in vivo, and exhibited a regular hexagonal
morphology and tight junctions, shown by ZO-1 staining
(Figure S3B).
We next assessed the integration of transplanted cells in the host
retina. Analysis of the combined RPE + RPC therapy at 1 week post-
injection showed that transplanted cells remained in the subretinal2021
Figure 7. Identification of RPE and RPC engrafted in
the RCS rat retina
(A) Immunostaining of retinal sections at 8 weeks PI with
RPE showing engraftment of GFP+ RPE cells in the host
RPE layer (n = 4 eyes). (a) Bright-field image corresponding
to Figure 6B showing pigmented GFP+ RPE cells. (b) GFP+
RPE cells expressed RPE65. (c and c’) Costaining with Rho
and opsin showing interaction of engrafted GFP+ RPE with
endogenous photoreceptors. (B) Immunostaining of retinal
sections at 8 weeks PI with RPC showing integration of RPC
into the ONL (n = 4 eyes). (d and e) Staining with Recov.
White dashed square in (d) indicates the area enlarged in
(d’). (f) Magnification of Figure 6B showing that GFP+ RPC
expressed Rho. (C) Immunostaining of retinal sections at
8 weeks PI with PRE + RPC (n = 5 eyes). (gj) Staining with
Recov, RPE65, and human antigen Ku80. White arrow-
heads indicate GFP+ RPC cells integrated to ONL in (d), (e),
(f), (g), and (h). GFP+ RPE cells integrate into the host RPE
layer as a discrete monolayer (i) or as clusters (g) and (j).
Scale bars, 25 mm. GFP in green. Nuclei were stained with
DAPI.
www.moleculartherapy.orgspace (Figure S4A), evidenced by GFP+ and Ku80+ cells (Figure S4B).
Because of the assortment of RPE cells and RPC, some transplanted
cells expressed RPE65, and others expressed CRX and opsin, and
only a few cells were proliferative (Ki67+), similar to what we
observed at 8 weeks (Figure S3C).
Notably, at 8 weeks postinjection, the conservation of the ONL was
evident in all cell treatments in the cryosection, as shown by the
expression of recoverin, rhodopsin, and opsin (photoreceptor
markers) in contrast to sham-injected retinas (Figure 6B). Most of
the transplanted RPE cells localized in the RPE layer, expressed
RPE65, acquired pigmentation, and interacted with endogenous
POS (Figures 6B, 6C, and 7, a, b, c, c’, and i). We also observed
that GFP+ RPE cells formed clusters in the subretinal space and
coexpressed RPE65 and Ku80, with no evidence of nuclei fragmen-
tation (Figure 7, i and j). Most transplanted RPCs remained in the
subretinal space (Figures 6B and 6C), but we observed some RPC
integrated into the ONL, coexpressing recoverin and extending their
projections through the layers (Figure 7, dh). We also observed
that in sham-injected eyes, ONL thickness was reduced and con-
tained less rows of nuclei in the ONL, whereas RPE- and RPC-
transplanted retinas maintained similar rows of nuclei and ONL
thickness. In contrast, in RPE + RPC-transplanted retinas, ONL
was thicker and contained more rows of nuclei (Figure 6D) (p <
0.001).
The number of GFP+ cells at 12 weeks postinjection was significantly
lower in all cell-transplanted eyes than in equivalent eyes studied at
8 weeks (Figure 6C), which resulted in a progressive reduction of
ONL and retinal thickness (Figure 6D). However, the conservationMolecularof the ONL was considerably better in the RPE + RPC-treated group,
as shown by the expression of rhodopsin, opsin, and recoverin by
endogenous photoreceptors (Figure 6C).
It has been described that retinas transplanted with photoreceptor
cells expressing fluorescent reporters can exchange cellular material
with host cells.41 In the RPC and combined RPE + RPC groups, we
also found some GFP signals in the inner nuclear layer and the gan-
glion cell layer, probably due to material transfer to neighboring rat
cells (Figure S3D), a phenomenon that was not observed in the
RPE cell therapy group.
Although RCS rats were immunosuppressed during cell treatments,
we observed activatedmicroglia andMüller glial cells in the subretinal
space surrounding GFP+ cells, which was more evident in the com-
bined RPE + RPC therapy, as evidenced by Iba1 and glutamine syn-
thetase staining (Figure S5). It is worthy of mention that the retinal
degeneration itself also triggered the activation of microglia and
Müller glia cell in the subretinal space of sham-injected retinas
(Figure S5).
Taken together, these results indicate that although most of the trans-
planted RPC remained in the subretinal space, the combined RPE +
RPC grafts survived longer and better conserved the ONL than
RPE- or RPC-only engrafted cells in the 12-week study period.
DISCUSSION
As part of our preclinical cell therapy studies, we successfully differ-
entiated hiPSC into RPE cells with phagocytic activity and developed
a new differentiation protocol to obtain RPC expressing precursorTherapy: Methods & Clinical Development Vol. 20 March 2021 697
Molecular Therapy: Methods & Clinical Developmentphotoreceptor markers. We established that the best RPC develop-
mental time window for transplantation in RCS rats at postnatal
day 21 is days 45–75, as immature progenitors from an earlier stage
(day 21) were unable to preserve retinal degeneration or visual func-
tion. Collectively, our data demonstrate for the first time that RPE
cells and RPC in a combined therapy can preserve both endogenous
photoreceptors and visual function in a manner superior to that using
only RPE cells or RPC. The rationale for choosing a transplantation
scheme combining RPE cells with RPC, both derived from hiPSC,
was based on our previous study,38 where we found that transplanta-
tion of RPE cells into the RCS rat model of severe photoreceptor
degeneration, caused by RPE phagocytosis dysfunction, was unable
to halt photoreceptor-degenerative processes and preserve visual
function.
Several retinal cell types have been successfully transplanted into
wild-type or degenerative animal models, and most were cells ob-
tained from the neuroretinas of young animals.28,42 These studies
show that neuroretinal cells can survive for long periods in the host
retina, integrate into the ONL, and mature as photoreceptors, form-
ing synaptic connections with bipolar cells,24 suggesting that the mul-
tipotent capacity of retinal progenitor cells is key to ensure the proper
formation of retinal structures, making them valuable for retinal
regeneration therapy. In terms of translating this approach to treat
patients, fetal retinal tissue may present limitations, including tissue
availability and ethical acceptability. Accordingly, derivation of
retinal cells from hESC and hiPSC represents the most promising
cell source for cell therapy. Several protocols have been used to
generate photoreceptors in 2D cultures and 3D retinal organoids
from both hESC and hiPSC,23,28–30,33,43–46 yielding different popula-
tions of postmitotic cone and rod photoreceptor precursors. Our dif-
ferentiation protocol in 2D yielded a population of RPC consisting of
an assortment of postmitotic precursors and more mature photore-
ceptor cells at day 45 of differentiation. The expression profile of
photoreceptor genes in our retinal RPC cultures is very similar to
that recently reported by Mellough et al.34 and reviewed by Llonch
et al.,47 who described the highest peak of hESC-derived photorecep-
tors expressing OPSINSW and RHODOPSIN between days 40 and 60
of differentiation. The failure of transplanted immature RPCs to sur-
vive in the host eye indicates that only postmitotic precursors may
survive and integrate.24 Indeed, we found that our retinal cells at
day 21 of differentiation failed to exert a protective effect on host pho-
toreceptors or visual function. In this line, the absence of mitotically
active or undifferentiated cells is particularly important to prevent
teratoma formations. Although the retinal progenitors at day 21 did
not have any effect on host retinas, no neoplastic structures were
evident, suggesting a postmitotic state of differentiated RPC from
that stage onward in differentiation.
We optimized the trans-scleral route of administration, in the form of
cell suspension, into the subretinal space of rat eyes to achieve high
survival rates. This offers major advantages over other routes or cell
sources: (1) it is technically easier and less traumatic than the trans-
corneal route, the transplantation of RPE sheets, or retinal patches;698 Molecular Therapy: Methods & Clinical Development Vol. 20 March(2) it allows the transplantation of an accurate cell number in a local-
ized area; and (3) it enables a better isolation, characterization, and
cryopreservation, as well as quality control of the transplantable cell
type. For therapeutic applications, the capacity of grafted cells trans-
planted subretinally to functionally integrate into the host retina relies
on their survival and migratory capacity.48 In the majority of cases,
however, this type of transplantation leads to a low number of cells
integrating into the correct layer, thus limiting the effectiveness of
the therapy. We show that although RPE cells and RPC survived up
to 12 weeks in the subretinal space and mainly exerted protective ef-
fects on endogenous photoreceptors, only a low number RPC and
RPE cells integrated into the correct layer. There are several possible
explanations for this. First, RCS rats exhibit severe photoreceptor loss,
but the RPE cell layer remains mostly intact. Accordingly, trans-
planted RPE cells may not have sufficient space to accommodate
into the layer close to Bruch’s membrane. Second, transplantation
of RPC in retinas retaining endogenous photoreceptors may lead to
low integration rates because of the presence of limiting membranes,
as we showed at 1 week post-transplantation (Figure S4). Recent
studies indicate that transplantation of cell suspensions into retinas
lacking photoreceptors might be a better model to study photore-
ceptor engraftment and synaptic connectivity with host bipolar
cells.20,45 Other studies point toward the use of chemical modulators
of glial response, such as matrix metalloproteinase 2 (MMP2) or ami-
noadipic acid, to reduce physical impairment of limiting membranes
and to enhance donor retinal integration into the ONL49–53. Finally,
transplantation of RPC into a neurodegenerative environment has
several implications that can reduce transplanted cell survival and
integration, such as gliosis, inflammation, and activated immune
response.
Histological analyses of eyes transplanted with combined RPE + RPC
revealed the preservation of retinal anatomy adjoining the engrafted
area and the rescue of photoreceptors, which correlates well with the
functional data. Of note, the fact that the area of photoreceptor rescue
extended beyond the limits of the injection site suggests a non-cell-
autonomous trophic effect of transplanted cells on the survival of
host photoreceptors rather than their replacement. This was previ-
ously observed by others,18,19 but the neuroprotective mechanism is
still unknown. Previous work by Klassen et al.54 found that mouse ret-
inas transplanted with RPC showed preservation of host photorecep-
tors by a rescue mechanism that was not previously observed after in-
travitreal injections,55 indicating that for cell rescue purposes,
subretinal injections are more effective. In addition, material transfer
between cells has been proposed as a new alternative mechanism in
which retinal cells can benefit.5 This novel concept is based on the ex-
change of cytoplasmic material between the engrafted retinal cells and
the host photoreceptors. Previous reports observed that the nonpho-
toreceptor fraction of retinal progenitor cells presented limited capac-
ity to integrate into the ONL upon transplantation and suggested that
the material transfer observed from donor to host cells could be
photoreceptor-photoreceptor specific.24,46,56–58 This is in accordance
with our results using the combined RPE + RPC therapy, where we
observed some degree of material exchange with the rat retina,31 likely2021
www.moleculartherapy.orgdue to RPCs rather than the RPE, since this phenomenon was not
evident in eyes injected with RPE cells alone. Thus, the fact that the
combined therapy induced conservation of host ONL despite the
minimal integration of transplanted RPC, in combination with
some cytoplasmic transfer, suggests that the efficacy of the combined
therapy is partially due to a neuroprotective effect rather than func-
tional integration.
Conclusions
We show here the potential benefit of combined RPC and RPE cell
therapy in the RCS rat model of retinitis pigmentosa. Cells not only
survived in the host retina but also were able to delay disease progres-
sion and preserve visual function better than RPC or RPE therapies.
In late-stage retinal degeneration, when the irreversible loss of photo-
receptors leads to blindness, the combined hiPSC-derived RPC and
RPE cell therapymight represent a more feasible and complete option
for cell replacement than RPC or RPE therapy alone.
MATERIALS AND METHODS
Cell culture conditions
The hiPSC line CBiPS30-4F-5,59 which was previously used to suc-
cessfully generate RPE cells,38 was obtained from the Spanish Stem
Cell Bank upon Ethics Review Board and competent authority
approval. Cells were cultured feeder free on Matrigel (Corning)-
coated plates and expanded in chemically defined mTeSR1 medium
(STEMCELL Technologies) at 37C with 5% (v/v) CO2. The medium
was changed every other day until cells were ready for passaging. Col-
onies were detached using 0.5 mM EDTA (Thermo Fisher Scientific)
for 2 min at room temperature.
hiPSC differentiation to RPE and RPCs
Differentiation of CBiPS30-4F-5 hiPSC to RPE cells was performed as
described.38 Briefly, hiPSC colonies on Matrigel (Corning)-coated
plates were expanded inmTeSR1medium (STEMCELL Technologies)
until they reached 70%confluence. Retinal inductionwas performed by
replacing mTeSR1 with RPE medium containing Dulbecco’s modified
Eagle’s medium (DMEM): nutrient mixture F-12 (DMEM/F12; Gibco)
with 10% knockout serum replacement (KSR; Gibco), 0.1 mM nones-
sential amino acids (Gibco), 1% N2 (Gibco), 2% B27 (Gibco), 0.1 mM
dexamethasone (Sigma), 10 mM b-glycerophosphate (Sigma), 20 ng/
mL human insulin growth factor (IGF)-1 (R&D Systems), and
10 mM nicotinamide (Sigma), which were replenished every other
day. After 6 weeks of differentiation, visible pigmented foci weremanu-
ally isolated and expanded in RPE medium on Matrigel-coated plates.
For purification and expansion, RPE cultures were treated with 0.05%
trypsin (Gibco) for 2 min to remove fibroblast-like cells, and then re-
maining attached RPE cells were disaggregated using 0.25% trypsin
and cultured in monolayers. For all experiments, hiPSC-RPE cells
expanded 2–4 times and were frozen in 10% DMSO in fetal bovine
serum medium. Lentiviral transduction and cell characterization are
described in Supplemental materials and methods.
Retinal differentiation was based on a published protocol39 with slight
modifications. When confluent, hiPSC colonies were dissociated intoMolecularsmall clumps, and EBs were formed in conical-bottom 96-well plates
inmTeSR1medium (STEMCELL Technologies). After 48 h, EBs were
transferred to low-attachment plates with retinal induction medium
(RIM) containing DMEM: nutrient mixture F-12 (DMEM/F12;
Gibco), 10% KSR (Gibco), 0.1 mM nonessential amino acids (Gibco),
1% N2 (Gibco), 2% B27 (Gibco), supplemented with 10 ng/mL
Noggin (STEMCELL Technologies), 10 ng/mL DKK-1 (STEMCELL
Technologies), 10 ng/mL IGF-1 (R&D Systems), and 5 ng/mL basic
fibroblast growth factor (bFGF; Millipore). At day 5, EBs were plated
onto Matrigel-coated plates (5–10 EBs per cm2) to facilitate rapid
conversion into retinal progenitors43 and were maintained in RIM
without KSR, which was changed every other day. To enrich for
retinal progenitors, neural rosettes were manually picked and
expanded onMatrigel-coated plates. From day 30, retinal progenitors
were cultured in RIM without KSR, supplemented with 10 ng/mL
IGF-1, 20 mM taurine, and 500 nM all-trans retinoic acid (Sigma) un-
til the end of the protocol. In addition, 10 mM g-secretase inhibitor,
DAPT (Sigma), a Notch inhibitor, was added to media from days
28 to 32. Before day 45 of retinal differentiation, RPCs destined for
subretinal injection were transduced with lentiviral particles carrying
a GFP reporter gene (cell characterization is described in Supple-
mental materials and methods).
Animals
All procedures were approved by the Animal Care and Use Commit-
tee of the Vall d’Hebron Research Institute and were performed in
accordance with the tenets of the European Community (86/609/
CEE) and the Association for Research in Vision and Ophthalmology.
Animals used were 21- to 24-day-old dystrophic (rdy2/p+) RCS rats,
which were maintained on a 12-h light/dark cycle with ad libitum
food and water. To avoid human cell graft rejection, animals were im-
munosuppressed by oral gavage with cyclosporin A 20 mg/kg/day
(Novartis Pharma AG). Treatment was maintained throughout the
entire experiment, starting 2 days before transplantation.
Surgery and transplantation
Before surgery, GFP-expressing differentiated RPE cells and RPCs
were dissociated in TrypLE Select (Gibco), neutralized, and passed
through a 70-mm filter to remove cell clumps. Cells suspended in
serum-free DMEM/F12 medium at 5  104 cells/mL. Four groups
of RCS rats were used for a single-cell injection (2 mL in total) into
the subretinal space at postnatal days 21–24 as follows (see Table 1):
group 1, transplantation of 100,000 RPE cells; group 2, cotransplan-
tation of 50,000 RPE cells and 50,000 RPC mixture (note that in
experiment #1, two additional animal groups were included for pilot
studies of transplantation of RPE + RPC at different time points of the
differentiation process to assess the best option); group 3, transplan-
tation of 100,000 RPC at days 4550; and group 4, injection of me-
dium as a control (sham). Animals were anesthetized with a mixture
of 2% isoflurane (Arrane; Baxter Laboratories)/1% O2 and main-
tained with a rat nasal mask. Pupils were dilated with tropicamide
(10 mg/mL Colircusi Tropicamida; Alcon Cusí Laboratories). Under
a surgical microscope, simple sutures were performed in the upper
eyelid and upper limbal conjunctiva with Prolene 7/0 EthiconTherapy: Methods & Clinical Development Vol. 20 March 2021 699
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tiva, and a 2-mm sclerotomy was performed using a 20G blade, 4 mm
from the limbus. 2 mL of cell suspension was loaded into a 32G blunt
needle attached to a 10-mL Nanofil syringe (World Precision Instru-
ments), which was introduced tangentially into the subretinal space
through the sclerotomy. Finally, the needle and securing sutures
were carefully removed, and a drop of tobramycin and dexametha-
sone (Tobradex 3 mg/mL + 1 mg/mL; Alcon Cusí Laboratories)
was topically administered just after surgery as a local anti-inflamma-
tory and antibiotic prophylaxis. Those eyes that did not present an
evident fluorescent bleb in the subretinal space assessed by fundus im-
aging and OCT were excluded from the study.
In vivo analyses
Animals were maintained over 12 weeks, and structural and func-
tional analyses were performed periodically by FFI, OCT, and Ganz-
feld ERG using the Micron III platform (Phoenix Research Labora-
tories). For all procedures, animals were anesthetized with inhaled
2% isofluorane and placed on a heating pad at 37C. Pupils were
dilated with a mixture of tropicamide and phenylephrine (100 mg/
mL Colircusí Fenilefrina; Alcon Cusí Laboratories), and 2%Methocel
gel (OmniVision) was administered to the cornea to favor contact
with the lens.
Color fundus and fluorescent images were taken at the day of sur-
gery and 1, 2, 4, 8, and 12 weeks postinjection using the Micron III
imaging microscope (Phoenix Research Laboratories). RPE and
RPC grafts were identified as green fluorescent spots in the eye
fundus under the retina. Images from different time points in the
same animal were compared to monitor the presence of the trans-
planted cells. Following FFI and with the animal still anesthetized,
OCT images were taken by image-guided tomography (Micron
IV-OCT2; Phoenix Research Laboratories). For each eye, the scan-
ner was placed over the injected area, and three images were taken
near the injection point. One image was also taken in a noninjected
area at the opposite site of the eye. Finally, the images were analyzed
with InSight 3D Voxeleron software for the quantitative assessment
of whole retina thickness and the photoreceptor layer. The percent-
age of preservation of total retina thickness and photoreceptor layer
thickness in Figure 4 was calculated by applying the following for-
mula, using the values of a noninjected area and the injected area of
the same eye:% preservation =
ðinjected area thicknessÞ  ðnon injected area thicknessÞ
non injected area thickness
 100:Functional responses of the retinas were recorded at 4, 8, and
12 weeks postinjection using the Phoenix Ganzfeld ERG system
(Phoenix Research Laboratories). Dark-adapted rats (12–16 h)
were anesthetized under dim red light, and pupils were dilated as
described. Three electrodes were placed on the tail (ground elec-700 Molecular Therapy: Methods & Clinical Development Vol. 20 Marchtrode), the head (reference electrode), and the cornea, located in
the objective lens (corneal electrode). Scotopic retinal responses
were recorded using light flashes (1 ms duration, light intensities
ranging from 1.1 to 1.9 log cd $ s $ m2, with 10 sweeps and
10- to 60-s intervals, depending on the intensity). Waveforms
were analyzed using LabScribe ERG software (Phoenix Research




At 8 and 12 weeks postinjection, eyes were enucleated and
dissected in PBS to remove cornea, lens, and retina. The posterior
eyecups were fixed in 4% (w/v) paraformaldehyde (PFA) for 1 h,
rinsed 3 times for 10 min with phosphate-buffered saline (PBS),
and flattened by making four radial incisions. For detection of
ZO-1, eyecups were subjected to immunochemistry, as described
below.
Histology
At 1, 8, or 12 weeks postinjection, eyes were enucleated and fixed
in 4% PFA overnight at 4C. After 3 rinses with PBS, eyes were
subjected to dehydration using a successive sucrose concentration
as follows: 15% for 30 min, 20% for 60 min, and 30% overnight,
all at 4C. Eyes were embedded in optimum cutting temperature
compound (Tissue-Tek), frozen, and stored at 80C. Thin serial
sections of 10 mm were cut using a Cryostat microtome (Leica)
and collected on Superfrost glass slides. Transversal cryosections
were stained with hematoxylin and eosin by standard protocols.
Images were acquired on an FSX100 microscope (Olympus Life
Sciences).
Immunohistochemistry
Cryosections and RPE flat mounts were washed in PBS and permea-
bilized and blocked in PBS containing 0.5% Triton X-100 and 6%
normal donkey serum (NDS; Millipore) for 1 h at room temperature.
Primary and secondary antibodies (see Table S2) were diluted in 0.1%
Triton X-100 and 6% NDS in PBS and incubated in a humidified
chamber overnight at 4C or 2 h at 37C, respectively. Slides were
mounted in mounting medium containing 40,6-diamidino-2-phenyl-
indole (DAPI), and images were obtained on a DMI6000 confocal mi-
croscopy (Leica Microsystems).Statistics
All quantitative data were analyzed using GraphPad Prism software
(GraphPad Software). The unpaired two-tailed Student’s t-test was
applied to determine statistical significance between 2 groups. For
more than 2 groups, 1- or 2-way ANOVA with a Tukey-corrected2021
www.moleculartherapy.orgpost hoc test was used. Statistical significance was considered at <0.05
with a confidence interval of 95%.
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